sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
|
alcohol
|
psychotropics
|
NONE
|
Guaifenesin_ddi.xml
|
DDI-DrugBank.d398.s0
|
DDI-DrugBank.d398.s0.p4
|
In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.
|
levodopa
|
papaverine
|
EFFECT
|
Carbidopa_ddi.xml
|
DDI-DrugBank.d47.s3
|
DDI-DrugBank.d47.s3.p1
|
Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.
|
CNS depressant drugs
|
INAPSINE
|
EFFECT
|
Droperidol_ddi.xml
|
DDI-DrugBank.d254.s0
|
DDI-DrugBank.d254.s0.p4
|
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
|
Duloxetine
|
imipramine
|
ADVISE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s9
|
DDI-DrugBank.d548.s9.p5
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
zileuton
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p25
|
Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
|
Pyrazolone Derivatives
|
aspirin
|
EFFECT
|
Aspirin_ddi.xml
|
DDI-DrugBank.d443.s3
|
DDI-DrugBank.d443.s3.p3
|
Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.
|
verapamil
|
TAMBOCOR
|
ADVISE
|
Flecainide_ddi.xml
|
DDI-DrugBank.d87.s19
|
DDI-DrugBank.d87.s19.p5
|
therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced.
|
contraceptives
|
Aprepitant
|
EFFECT
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s20
|
DDI-DrugBank.d382.s20.p0
|
Reported examples of this interaction include the following: Antibiotics: Rifampin is a potent inducer of CYP3A4.
|
Antibiotics
|
CYP3A4
|
NONE
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s47
|
DDI-DrugBank.d143.s47.p1
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
Probenecid
|
clofibrate
|
MECHANISM
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p22
|
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.
|
prednisolone
|
doxycycline
|
NONE
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s16
|
DDI-DrugBank.d249.s16.p22
|
Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;
|
Amphetamines
|
sympathomimetic agents
|
EFFECT
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s7
|
DDI-DrugBank.d236.s7.p8
|
Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L;
|
Theophylline
|
acetaminophen
|
MECHANISM
|
11206047.xml
|
DDI-MedLine.d111.s10
|
DDI-MedLine.d111.s10.p0
|
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
|
erythromycin
|
almotriptan
|
ADVISE
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s11
|
DDI-DrugBank.d299.s11.p13
|
Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
|
SPRYCEL
|
itraconazole
|
MECHANISM
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s1
|
DDI-DrugBank.d48.s1.p1
|
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.
|
bromocriptine mesylate
|
pimozide
|
EFFECT
|
Bromocriptine_ddi.xml
|
DDI-DrugBank.d272.s2
|
DDI-DrugBank.d272.s2.p3
|
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
|
FLOLAN
|
digoxin
|
NONE
|
Epoprostenol_ddi.xml
|
DDI-DrugBank.d241.s3
|
DDI-DrugBank.d241.s3.p0
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
levothyroxine sodium
|
furosemide
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p7
|
Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
|
erythromycin
|
disopyramide
|
INT
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s24
|
DDI-DrugBank.d522.s24.p4
|
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of beta2-agonists.
|
steroids
|
beta2-agonists.
|
EFFECT
|
Formoterol_ddi.xml
|
DDI-DrugBank.d103.s4
|
DDI-DrugBank.d103.s4.p19
|
Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
|
alcohol
|
insulin
|
EFFECT
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s3
|
DDI-DrugBank.d313.s3.p9
|
Caution should be used if ibuprofen is administered concomitantly with methotrexate.
|
ibuprofen
|
methotrexate
|
ADVISE
|
Ibuprofen_ddi.xml
|
DDI-DrugBank.d415.s7
|
DDI-DrugBank.d415.s7.p0
|
Both digoxin and COREG slow AV conduction.
|
digoxin
|
COREG
|
EFFECT
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s12
|
DDI-DrugBank.d269.s12.p0
|
A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.
|
FOSCAVIR
|
pentamidine
|
INT
|
Foscarnet_ddi.xml
|
DDI-DrugBank.d511.s0
|
DDI-DrugBank.d511.s0.p0
|
The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.
|
allopurinol
|
chlorpropamide
|
EFFECT
|
Allopurinol_ddi.xml
|
DDI-DrugBank.d413.s21
|
DDI-DrugBank.d413.s21.p0
|
Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
|
Lodine
|
cyclosporine
|
MECHANISM
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s7
|
DDI-DrugBank.d219.s7.p1
|
As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.
|
nondepolarizing neuromuscular blocking agents
|
carbamazepine
|
EFFECT
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s6
|
DDI-DrugBank.d267.s6.p2
|
Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.
|
Aprepitant
|
tolbutamide
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s4
|
DDI-DrugBank.d382.s4.p1
|
Synergism has been shown between halothane anesthesia and intravenously administered labetalol HCl.
|
halothane
|
labetalol HCl
|
EFFECT
|
Labetalol_ddi.xml
|
DDI-DrugBank.d412.s6
|
DDI-DrugBank.d412.s6.p0
|
Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
|
quinolones
|
quinolones
|
NONE
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s1
|
DDI-DrugBank.d78.s1.p11
|
Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
|
anticonvulsant medications
|
folic acid
|
NONE
|
Folic Acid_ddi.xml
|
DDI-DrugBank.d425.s1
|
DDI-DrugBank.d425.s1.p8
|
Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.
|
Aprepitant
|
phenytoin
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s5
|
DDI-DrugBank.d382.s5.p0
|
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
|
platelet inhibitors
|
digoxin
|
NONE
|
Fondaparinux sodium_ddi.xml
|
DDI-DrugBank.d15.s0
|
DDI-DrugBank.d15.s0.p24
|
Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin.
|
cetirizine
|
ketoconazole
|
NONE
|
Cetirizine_ddi.xml
|
DDI-DrugBank.d393.s0
|
DDI-DrugBank.d393.s0.p2
|
Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
|
TARCEVA
|
atazanavir
|
ADVISE
|
Erlotinib_ddi.xml
|
DDI-DrugBank.d456.s1
|
DDI-DrugBank.d456.s1.p1
|
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).
|
ACEI
|
ARB
|
NONE
|
Eplerenone_ddi.xml
|
DDI-DrugBank.d20.s4
|
DDI-DrugBank.d20.s4.p20
|
When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.
|
Itraconazole
|
rifampin
|
MECHANISM
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s18
|
DDI-DrugBank.d165.s18.p1
|
Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.
|
probenecid
|
nitrofurantoin
|
MECHANISM
|
Nitrofurantoin_ddi.xml
|
DDI-DrugBank.d276.s2
|
DDI-DrugBank.d276.s2.p4
|
Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.
|
BEXTRA
|
lithium
|
ADVISE
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s21
|
DDI-DrugBank.d328.s21.p2
|
Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
|
Cholestyramine
|
penicillin G
|
MECHANISM
|
Cholestyramine_ddi.xml
|
DDI-DrugBank.d566.s0
|
DDI-DrugBank.d566.s0.p6
|
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
|
reserpine
|
amphetamines
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s0
|
DDI-DrugBank.d236.s0.p17
|
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.
|
imidazoles
|
amphotericin B
|
EFFECT
|
Amphotericin B_ddi.xml
|
DDI-DrugBank.d318.s8
|
DDI-DrugBank.d318.s8.p35
|
A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.
|
glyburide
|
ciprofloxacin
|
INT
|
Glibenclamide_ddi.xml
|
DDI-DrugBank.d178.s7
|
DDI-DrugBank.d178.s7.p0
|
At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).
|
methotrexate
|
rofecoxib
|
MECHANISM
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s21
|
DDI-DrugBank.d210.s21.p3
|
Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.
|
probenecid
|
cefditoren pivoxil
|
MECHANISM
|
Cefditoren_ddi.xml
|
DDI-DrugBank.d550.s4
|
DDI-DrugBank.d550.s4.p7
|
By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.
|
DIAMOX
|
primidone
|
MECHANISM
|
Acetazolamide_ddi.xml
|
DDI-DrugBank.d368.s3
|
DDI-DrugBank.d368.s3.p2
|
Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant.
|
Chloral hydrate
|
anticoagulant agents
|
INT
|
1109248.xml
|
DDI-MedLine.d106.s8
|
DDI-MedLine.d106.s8.p1
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
rifadin
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p38
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
levothyroxine sodium
|
clofibrate
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p3
|
Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.
|
diclofenac
|
methotrexate
|
MECHANISM
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s4
|
DDI-DrugBank.d249.s4.p1
|
Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents.
|
antidepressant drugs
|
hypoglycemic agents
|
INT
|
11151029.xml
|
DDI-MedLine.d21.s2
|
DDI-MedLine.d21.s2.p0
|
Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.
|
naproxen sodium
|
Neurontin
|
MECHANISM
|
Gabapentin_ddi.xml
|
DDI-DrugBank.d438.s15
|
DDI-DrugBank.d438.s15.p3
|
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
|
Curariform muscle relaxants
|
Coly-Mycin M
|
EFFECT
|
Colistimethate_ddi.xml
|
DDI-DrugBank.d250.s2
|
DDI-DrugBank.d250.s2.p5
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
monoamine oxidase inhibitors
|
sertraline
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p6
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
alprazolam
|
theophylline
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p123
|
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.
|
HMGCoA reductase inhibitors
|
pravastatin
|
NONE
|
19489169.xml
|
DDI-MedLine.d119.s2
|
DDI-MedLine.d119.s2.p2
|
Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
|
midazolam
|
triazolam
|
NONE
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s11
|
DDI-DrugBank.d165.s11.p2
|
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
|
erythromycin
|
budesonide
|
ADVISE
|
Budesonide_ddi.xml
|
DDI-DrugBank.d144.s1
|
DDI-DrugBank.d144.s1.p20
|
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
|
diuretics
|
anticoagulants
|
NONE
|
Epoprostenol_ddi.xml
|
DDI-DrugBank.d241.s3
|
DDI-DrugBank.d241.s3.p19
|
Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy.
|
anticonvulsant agents
|
cisplatin
|
MECHANISM
|
Cisplatin_ddi.xml
|
DDI-DrugBank.d145.s0
|
DDI-DrugBank.d145.s0.p0
|
Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
|
phenytoin
|
clonazepam
|
MECHANISM
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s5
|
DDI-DrugBank.d333.s5.p2
|
PEGASYS contains benzyl alcohol.
|
PEGASYS
|
benzyl alcohol
|
NONE
|
Peginterferon alfa-2a_ddi.xml
|
DDI-DrugBank.d196.s36
|
DDI-DrugBank.d196.s36.p0
|
Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.
|
descarboethoxyloratadine
|
loratadine
|
NONE
|
Loratadine_ddi.xml
|
DDI-DrugBank.d258.s1
|
DDI-DrugBank.d258.s1.p3
|
The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
|
antipsychotic drug
|
amitriptyline
|
EFFECT
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s0
|
DDI-DrugBank.d86.s0.p4
|
It was concluded that, although gentamycin did augment the neuromuscular blockade of atracurium, the effect was minimal.
|
gentamycin
|
atracurium
|
EFFECT
|
8542840.xml
|
DDI-MedLine.d90.s11
|
DDI-MedLine.d90.s11.p0
|
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.
|
phenobarbital
|
phenobarbital
|
NONE
|
11206047.xml
|
DDI-MedLine.d111.s14
|
DDI-MedLine.d111.s14.p11
|
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
|
phenothiazines
|
DILAUDID
|
EFFECT
|
Hydromorphone_ddi.xml
|
DDI-DrugBank.d26.s0
|
DDI-DrugBank.d26.s0.p20
|
Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids, estrogens, oral contraceptives containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.
|
estrogens
|
salicylates
|
NONE
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s24
|
DDI-DrugBank.d54.s24.p26
|
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.
|
STRATTERA
|
quinidine
|
ADVISE
|
Atomoxetine_ddi.xml
|
DDI-DrugBank.d11.s3
|
DDI-DrugBank.d11.s3.p2
|
Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
|
Cholestyramine
|
digitalis
|
MECHANISM
|
Cholestyramine_ddi.xml
|
DDI-DrugBank.d566.s0
|
DDI-DrugBank.d566.s0.p11
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
nondepolarizing agents
|
aminoglycosides
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p2
|
Acitretin: Interferes with the contraceptive effect of microdosed progestin-containing minipill preparations.
|
Acitretin
|
progestin
|
EFFECT
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s4
|
DDI-DrugBank.d485.s4.p0
|
Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.
|
anticoagulants
|
hypoglycemic agents
|
MECHANISM
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s88
|
DDI-DrugBank.d64.s88.p0
|
Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
|
ALPHAGAN P
|
opiates
|
ADVISE
|
Brimonidine_ddi.xml
|
DDI-DrugBank.d138.s0
|
DDI-DrugBank.d138.s0.p3
|
ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
|
ZEBETA
|
phenylalkylamine
|
ADVISE
|
Bisoprolol_ddi.xml
|
DDI-DrugBank.d476.s3
|
DDI-DrugBank.d476.s3.p2
|
Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
NSAIDs
|
salicylates
|
NONE
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s14
|
DDI-DrugBank.d460.s14.p6
|
Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.
|
dopamine HCl
|
cyclopropane
|
ADVISE
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s10
|
DDI-DrugBank.d325.s10.p0
|
Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
|
tricyclic antidepressants
|
Type 1C antiarrhythmics
|
ADVISE
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s16
|
DDI-DrugBank.d202.s16.p3
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
buspirone
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p4
|
Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
|
Monoamine oxidase (MAO) inhibitors
|
selegiline
|
NONE
|
L-Tryptophan_ddi.xml
|
DDI-DrugBank.d63.s0
|
DDI-DrugBank.d63.s0.p6
|
Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
|
benzodiazepine class
|
nonbarbiturate hypnotics
|
EFFECT
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s7
|
DDI-DrugBank.d333.s7.p3
|
Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.
|
anticoagulants
|
chlorpropamide
|
MECHANISM
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s88
|
DDI-DrugBank.d64.s88.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
diflunisal
|
prolonged narcotics
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p804
|
Oral Hypoglycemic Agents: In pharmacokinetic studies of MEVACOR in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide
|
Hypoglycemic Agents
|
glipizide
|
NONE
|
Lovastatin_ddi.xml
|
DDI-DrugBank.d567.s22
|
DDI-DrugBank.d567.s22.p1
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
verapamil
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p24
|
Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable
|
phenytoin
|
valproate
|
EFFECT
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s15
|
DDI-DrugBank.d40.s15.p2
|
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
|
benzodiazepines
|
diltiazem
|
NONE
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s8
|
DDI-DrugBank.d131.s8.p37
|
Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
|
Carbamazepine
|
isoniazid
|
ADVISE
|
Isoniazid_ddi.xml
|
DDI-DrugBank.d187.s7
|
DDI-DrugBank.d187.s7.p15
|
Antihypertensives: Amiodarone should be used with caution in patients receiving -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
|
Antihypertensives
|
verapamil
|
NONE
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s41
|
DDI-DrugBank.d143.s41.p5
|
A clinical interaction study was also conducted with alosetron and the CYP3A4 substrate cisapride.
|
alosetron
|
cisapride
|
NONE
|
Alosetron_ddi.xml
|
DDI-DrugBank.d364.s18
|
DDI-DrugBank.d364.s18.p0
|
Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.
|
antihistamines
|
barbiturates
|
EFFECT
|
Clemastine_ddi.xml
|
DDI-DrugBank.d309.s0
|
DDI-DrugBank.d309.s0.p1
|
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
|
epinephrine
|
monoamine oxidase inhibitors
|
EFFECT
|
Bupivacaine_ddi.xml
|
DDI-DrugBank.d153.s0
|
DDI-DrugBank.d153.s0.p5
|
If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
|
desipramine
|
diazepam
|
EFFECT
|
Desipramine_ddi.xml
|
DDI-DrugBank.d386.s23
|
DDI-DrugBank.d386.s23.p32
|
Propanolol: The pharmacokinetics of almotriptan were not affected by coadministration of propranolol.
|
Propanolol
|
propranolol
|
NONE
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s5
|
DDI-DrugBank.d299.s5.p1
|
Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.
|
beta-blockers
|
epinephrine
|
EFFECT
|
Betaxolol_ddi.xml
|
DDI-DrugBank.d489.s8
|
DDI-DrugBank.d489.s8.p0
|
Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
|
Cholestyramine
|
propranolol
|
MECHANISM
|
Cholestyramine_ddi.xml
|
DDI-DrugBank.d566.s0
|
DDI-DrugBank.d566.s0.p4
|
Flurbiprofen did not affect the pharmacokinetic profile of either drug, and the mechanism under lying the interference with propranolols hypotensive effect is unknown.
|
Flurbiprofen
|
propranolol
|
INT
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s10
|
DDI-DrugBank.d529.s10.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
prolonged narcotics
|
sulfonamides
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1386
|
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
|
Fluoxetine
|
Rifampin
|
NONE
|
Delavirdine_ddi.xml
|
DDI-DrugBank.d251.s0
|
DDI-DrugBank.d251.s0.p28
|
There have been reports of theophylline-related side-effects in patients on concomitant theophylline-quinolone therapy.
|
theophylline
|
quinolone
|
EFFECT
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s1
|
DDI-DrugBank.d562.s1.p2
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.